Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple Sclerosis  by Prosser, Lisa A. et al.
Volume 7 • Number 5 • 2004
V A L U E  I N  H E A L T H
© ISPOR 1098-3015/04/$15.00/554 554–568 554
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152004 Blackwell Publishing75554568Original ArticleCEA of  Immunomodulatory Treatments for MSProsser et al.
Address correspondence to: Lisa A. Prosser, Department of
Ambulatory Care and Prevention, Harvard Medical School
and Harvard Pilgrim Health Care, 133 Brookline Avenue,
6th ﬂoor, Boston, MA 02215 USA. E-mail:
lprosser@hms.harvard.edu
Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, 
and Glatiramer Acetate in Newly Diagnosed Non-primary 
Progressive Multiple Sclerosis
Lisa A. Prosser, PhD,1 Karen M. Kuntz, ScD,2 Amit Bar-Or, MD, FRCPC,3 Milton C. Weinstein, PhD2
1Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA, USA; 
2Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA; 
3Department of Neurology and Neurosurgery, Montreal Neurological Institute and McGill University, Montreal, QC, Canada
ABSTRACT
Objective: To perform a cost-effectiveness analysis of
three immunomodulatory treatments for newly diagnosed
nonprimary progressive MS: interferon beta-1a, inter-
feron beta-1b, and glatiramer acetate.
Methods: We developed a state-transition model to esti-
mate the health effects and costs associated with inter-
feron beta-1a, interferon beta-1b, glatiramer acetate, and
no treatment for hypothetical cohorts of men and women
with non-primary progressive MS. We used the Expanded
Disability Status Scale as the measure of disability and
included both relapses and disease progression in the
model. We evaluated treatment strategies assuming a 10-
year treatment duration using the societal perspective. We
elicited preferences for disability and treatment states
using standard-gamble questions and modeled the disu-
tility associated with treatment administration and side
effects explicitly. Main outcome measures were net gains
in quality-adjusted life expectancy and incremental cost-
effectiveness ratios in dollars per quality-adjusted life year
(QALY) gained.
Results: For treatment duration of 10 years for newly
diagnosed non-primary progressive MS, interferon beta-
1a yielded  the  largest  gain  in  quality-adjusted  life
expectancy with an incremental cost-effectiveness ratio of
$2,200,000/QALY for women and $1,800,000/QALY for
men, compared with no treatment. For a 5-year treatment
duration, a “no treatment” strategy yielded more quality-
adjusted life years than any of the treatment strategies.
Cost-effectiveness ratios were similar for all three immu-
nomodulatory treatments evaluated.
Conclusions: Cost-effectiveness results for all three
immunomodulatory treatments for MS were unfavorable
in the simulated study population under a wide range of
assumptions. For treatment duration less than or equal to
5 years, expected beneﬁts of treatment may not outweigh
disutility associated with side effects and treatment
discomfort.
Keywords: beta interferon, cost-effectiveness, glatiramer
acetate, multiple sclerosis.
Introduction
Multiple sclerosis (MS) is an immune-mediated
demyelinating disease of the central nervous system
characterized by bouts of neurologic symptoms (or
relapses) and often increasing disability [1]. MS
affects approximately 350,000 people in the United
States, and annual costs of the disease including
costs of lost wages and informal care are estimated
to exceed $9 billion [2].
The introduction of immunomodulatory treat-
ments (interferon beta-1a, interferon beta-1b, and
glatiramer acetate) represented a critical advance in
available treatments for MS, offering beneﬁts to a
patient population with few treatment alternatives.
These treatments have been shown both to reduce
the number of relapses and slow the progression of
disease  [3–7].  At  the  same  time,  these  treatments
are expensive (annual drug costs of $10,000 to
$13,000) and are associated with uncomfortable
side effects (ﬂu-like symptoms and injection-site
reactions) that place a burden on patients who ini-
tiate treatment. Given these treatment characteris-
tics, we performed a cost-effectiveness analysis to
gain insight into the tradeoffs between the costs and
health effects of available treatments for newly
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diagnosed patients with non-primary progressive,
or “bout onset,” MS.
Methods
The Simulation Model
We developed a state-transition model to simulate
the natural history, treatment effects, and costs of
four strategies for hypothetical cohorts of patients
with  non-primary  progressive  MS:  1)  treatment
with interferon beta-1a (Avonex); 2) treatment with
interferon beta-1b (Betaseron); 3) treatment with
glatiramer acetate (Copaxone); and 4) no treat-
ment. Natural history is deﬁned as progression of
disease in the absence of immunomodulatory treat-
ments. For example, this assumes that relapses are
treated with steroids but that this treatment does
not alter the long-term course of the disease. The
model includes the costs and health outcomes asso-
ciated with treatment of relapses and accumulated
disability, as deﬁned by Expanded Disability Status
Scale level. We simulated separate cohorts of newly
diagnosed 30-year-old women and men with non-
primary progressive MS, which includes patients
with relapsing remitting, secondary progressive,
and progressive relapsing MS. We used a time frame
of 10 years for the base case analysis, although the
simulation model can be run for any length of time
up to 40 years. We assumed a societal perspective
for the base case analysis and adhered to the rec-
ommendations for a reference case analysis as
described by the US Panel on Cost-effectiveness in
Health and Medicine [8].
A  recently  developed  classiﬁcation  system  for
MS separates patients into four groups: relapsing
remitting, secondary progressive, primary progres-
sive, and progressive relapsing [9]. While physicians
use these categories to describe individual patients,
a prevailing view is that MS should be treated as a
broad spectrum of disease activity [10]. This view is
supported by the natural history data on rates of
disease progression; disability survival curves do
not differ by MS type at the time of diagnosis.
Because patients with primary progressive MS are
the only group that can be identiﬁed in early stages
of the disease as having a worse prognosis and are
therefore treated differently, these patients are
excluded from the current analysis. Base case
assumptions in the model reﬂect the characteristics
of a cohort with newly diagnosed MS. Sensitivity
analyses can be run to evaluate cohorts of patients
with secondary progressive MS.
Long-term natural history studies have shown
disease progression to be correlated with a number
of prognostic factors: age at onset, gender, relapse
frequency, and type of symptoms at onset [11].
Because sufﬁciently detailed data are available only
for modeling the effect of gender on disease progres-
sion, our analysis incorporated only gender-speciﬁc
rates of disease progression.
A simpliﬁed schematic of the model is presented
in Figure 1. We deﬁned disease status based on the
most widely used scale for categorizing patients
with MS, the Expanded Disability Status Scale
(EDSS). EDSS levels were grouped into ﬁve health
states for modeling disease progression (Table 1).
These ﬁve EDSS levels are generally regarded as the
key markers of disability for patients with MS [11].
The distribution of EDSS levels among the MS pop-
ulation is bimodal with peaks at 1 and 6 [11].
For the base case analysis, all patients start out in
the  model  with  No/Few  Limitations  (EDSS  level
0–2.5). Additional analyses simulated a treatment
strategy of delaying initiation of treatment until
patients progressed to Moderate Limitations (EDSS
level 3–5.5). In these analyses, all patients start out
in the model with Moderate Limitations. In any
given month (cycle length) in the model, a patient
can either remain in their EDSS-deﬁned health state
or progress to the next disability level. We assumed
Figure 1 Model overview.
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that patients progress in only one direction on the
disability status scale. Although some patients will
spontaneously improve in the short term, one-way
progression is consistent with the long-term natural
history data for MS [11]. In addition to disability
status, patients with an EDSS level less than six have
a probability of experiencing a relapse (an episode
of MS symptoms and signs), that can be categorized
into mild/moderate or severe according to their rat-
ing on the Neurological Rating Scale (Table 1) [3].
Each relapse is assumed to last for 1 month based
on data from two published studies [1,3]. Patients
can die from MS or from other causes.
The Data
Disease  progression.  We performed a literature
review to identify natural history studies with data
on disease progression in MS [11–17]. We identiﬁed
two studies that report changes in disability levels
over time and did not contain study populations
with signiﬁcant selection bias [13,14]. Excluding
data for patients with primary progressive MS, the
combined data from those two studies represented a
sample of more than 400 patients with a mean age
at onset of 30 years and an average follow-up of
more than 20 years. The resulting base case esti-
mates for monthly transition probabilities derived
from those studies are listed in Table 2. Estimates of
disease progression for sensitivity analysis in sec-
ondary progressive patients also used these studies
[13,14].
Relapses. Relapse rates from three natural history
studies were combined to estimate the monthly
transition probability for experiencing a relapse
(Table 2) [12,18,19]. The probability that a relapse
is severe was estimated from published clinical trials
(Table 2) [3].
We assumed that relapse rates were the same for
patients in the less disabled chronic states (i.e.,
EDSS < 6) and equal to zero for more-disabled
patients (EDSS ≥ 6). While data show that relapse
rates decrease as chronic disability increases [19],
we simpliﬁed this relationship by assuming that
less-disabled patients experience relapses and more-
disabled patients do not.
Mortality. We assumed that patients die from MS
(EDSS 10) only after progressing through all previ-
ous EDSS levels. While there will be some patients
for whom this is not the case, 89% of MS patients
are signiﬁcantly disabled (unable to walk) prior to
death [20]. Patients can also die from competing
causes of death throughout the progression of MS.
Non-MS mortality rates vary by year of age in the
model so that as age increases, non-MS mortality
also increases. Mortality rates were stratiﬁed by age
and gender using data from the 1998 US life tables
[21]. Consistent with natural history data, MS
patients in the model experience only a small
decrease in life expectancy (less than 2 years) as
compared with the general population [13,14].
Treatment Effects
The effects of treatment were simulated by a percent
reduction in the probabilities of relapse and disease
progression (Table 2). Estimates of the effects were
derived from clinical trial results for interferon beta-
1a, interferon beta-1b, and glatiramer acetate [3–7].
Treatment effects reported in clinical trials were
adjusted to account for patients who discontinued
treatment during the trial. In other words, our treat-
ment estimates are for patients who maintained
treatment for the duration of the trial.
Discontinuation rates reported for these treat-
ments are high and were modeled separately in the
analysis. For the base case analysis, we estimated
discontinuation rates from those reported in clinical
trials and open-label studies (Table 2) [1,4,6,7,22–
26]. Patients were assumed to discontinue at a
Table 1 Description of  health states for disease progression
Health states Description
No/Few Limitations (EDSS 0–2.5) No MS symptoms (0) to minimal disability in two functional systems (2.5).
Moderate Limitations (EDSS 3–5.5) Moderate disability in one area, or mild disability in up to four areas, but still able to walk unassisted and 
accomplish full daily activities (3) to disability which precludes full daily activities, but still able to walk 
unassisted (5.5).
Walking Aid or Wheelchair
(EDSS 6–7.5)
Requires walking aid such as cane, crutch, or brace to walk 100 meters (6) to restricted to wheelchair 
(7–7.5).
Restricted to Bed (EDSS 8–9.5) Restricted to bed with some ability to self-care (8) to requiring assistance for all activities of  daily living 
(9–9.5).
Death (EDSS 10) Death due to MS
No Relapse Diagnosed with multiple sclerosis but not currently experiencing a relapse
Mild/Moderate Relapse Experiencing a mild relapse (deﬁned as a change of  0–14 points on the NRS)
Severe Relapse Experiencing a severe relapse which can require hospitalization (deﬁned as a change in more than 14 
points on the NRS)
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constant rate during the ﬁrst 3 years of treatment.
After 3 years, the discontinuation rate was assumed
to be zero (i.e., all patients who discontinue treat-
ment will have done so by the end of the third year
of treatment).
Quality  of  life
Health outcomes were measured in the model using
quality-adjusted life years (QALYs). The quality-
adjusted life year is a preference-based measure that
incorporates both morbidity and mortality effects
[8]. Quality-of-life adjustments were made for each
level of chronic disability (MS health states), type
and presence of relapse, and discomfort associated
with treatments (Table 3). Treatment-related qual-
ity adjustments were assumed to last for the ﬁrst
6 months of treatment only [24,27]. Quality adjust-
ments were based on health- and treatment-state
Table 2 Transition probabilities
Variable Base case estimate Range for sensitivity analysis Sources
Estimated monthly transition probability for progressing to next level of  disability (per 1000):
EDSS 0–2.5
Men 4.6117 +/– 50% base case 13, 14
Women 4.2642
EDSS 3–5.5
Men 9.5498 13, 14
Women 8.8283
EDSS 6–7.5
Men 3.7231 13, 14
Women 3.4425
EDSS 8–9.5
Men 0.9897 13, 14
Women 0.9151
Monthly probability of  a relapse* 0.0755 0.0325, 0.12 12, 18, 19
Probability of  a severe relapse, given that a relapse has occurred 0.23 0, 0.5 3
Probability that a severe relapse is treated on an inpatient basis 1 0, 1 Expert opinion
Treatment effects
Glatiramer acetate (20 mg SC, every day)
Percent reduction in relapse rates 34.98 30.17, 40.74 7
Percent reduction in probability of  disease progression† 13.20 9.24, 17.16 7
Interferon beta-1a (30 mg IM, 1 ¥/week)
Percent reduction in relapse rates 19.14 13.40, 24.89 4, 5
Percent reduction in probability of  disease progression† 38.72 27.11, 50.34 4, 5
Interferon beta-1b (8 miu SC, every other day)
Percent reduction in relapse rates 37.64 26.34, 48.93 3, 6
Percent reduction in probability of  disease progression† 31.00 21.70, 40.29 3, 6
Monthly probability of  discontinuing treatment‡
Glatiramer acetate 0.0154 0.0108, 0.0200 7
Interferon beta-1a 0.0125 0.0087, 0.0162 15, 22
Interferon beta-1b 0.0183 0.0128, 0.0238 1, 6, 23–26
*Weighted average of  relapse rates from the three referenced studies.
†Based on 2-year clinical trial data.
‡First 3 years on treatment only.
Table 3 Quality-of-life adjustments
Quality adjustments Base case estimate Range for sensitivity analysis* Sources
By disability level (in utilities)
No/few limitations 0.954 0.971, 0.936 28
Moderate limitations 0.870 0.917, 0.823 28
Walking aid or wheelchair 0.769 0.858, 0.680 28
Restricted to bed 0.491 0.609, 0.372 28
Dead from MS 0
By relapse severity (in disutilities)†
Mild/moderate -0.091 -0.063, -0.119 28
Severe -0.302 -0.238, -0.366 28
By treatment (in disutilities)†,‡
Glatiramer acetate -0.066 -0.020, -0.113 28
Interferon beta-1a -0.115 -0.045, -0.185 28
Interferon beta-1b -0.204 -0.061, -0.346 28
Pooled -0.130 -0.072, -0.188 28
*Ranges based on 95% conﬁdence intervals.
†Reduction from utility for each disability level.
‡Quality adjustments applied for ﬁrst 6 months on treatment only, assumed to be zero for treatment beyond the ﬁrst 6 months [25,28].
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utilities elicited from members of the community
using the standard-gamble method [28].
Community-based rather than patient utilities were
used in the base-case analysis to be consistent with
recommendations from the US Public Health Serv-
ice Panel on Cost-Effectiveness in Health and Med-
icine [8]. Subjects for the utility assessments were a
convenience sample from San Diego, CA, USA. Util-
ities for described MS health states were assessed
during a 30-minute computer-administrated inter-
view using U-Titer II software with an interviewer
present (LAP) [28]. QALYs were discounted at 3%
per year.
Costs
Costs included direct health care costs, including
costs of physician visits, hospital stays, drugs, home
care, and equipment, as well as costs of informal
care, and patient time costs for administering treat-
ment. Costs of lost work productivity were not
included in the base case analysis, under the
assumption that lost income is reﬂected in the dis-
utility weights, and in keeping with the reference-
case criterion of the US Panel on Cost-Effectiveness
in Health and Medicine [8]. All costs have been
adjusted to 1999 dollars using the GDP price index
[29] and were discounted at 3% per year.
Treatment costs. Treatment costs included the costs
of medication, laboratory tests, and patient time
required to administer medication (Table 4). Medi-
cation costs were calculated using 1999 average
wholesale price [30]. Mean time for administering
an injection was 15 minutes. We estimated the value
of patient time for administering medication by
multiplying the time by average US hourly wage
rates [31]. Laboratory tests to monitor liver func-
tion were assumed to occur every 3 months for
interferon beta-1a and interferon beta-1b [32].
Relapse-related  costs. For the base case analysis,
mild/moderate relapses were assumed to require one
physician outpatient visit with no additional treat-
ment [33]. We assumed that all severe relapses were
treated on an inpatient basis for intravenous steroid
Table 4 Cost inputs
Health states or events
Base case estimate
(in 1999 US dollars)
Range for sensitivity
analysis Sources
Monthly treatment costs* +/– 50% of  base case
Glatiramer acetate
Men $1006
Medication Costs $877 30
Laboratory Costs $0 32
Patient Time Costs $129 31
Women $973
Medication Costs $877 30
Laboratory Costs $0 32
Patient Time Costs $96 31
Interferon beta-1a
Men $956
Medication Costs $923 30
Laboratory Costs $16 32
Patient Time Costs $17 31
Women $952
Medication Costs $923 30
Laboratory Costs $16 32
Patient Time Costs $13 31
Interferon beta-1b
Men $1175
Medication Costs $1095 30
Laboratory Costs $16 32
Patient Time Costs $65 31
Women $1159
Medication Costs $1095 30
Laboratory Costs $16 32
Patient Time Costs $48 31
Relapse:
Outpatient treatment of  mild/moderate relapse $57.50 $0, $100 33
Inpatient treatment of  severe relapse $5270 +/– 50% of  base case †
Monthly costs associated with each disability level
No/few limitations – $0, $50 2, 36
Moderate limitations $10 $0, $100 2, 36
Walking aid or wheelchair $310 $260, $1,500 2, 36
Restricted to bed $860 $530, $10,000 2, 36
*Includes costs of  medication, laboratory tests, and patient time.
†Conﬁdential cost data from large teaching hospital in Boston, MA.
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treatment. Using data from the cost-accounting sys-
tem of a large teaching hospital in Boston, MA, we
found that the mean cost of treating a relapse on an
inpatient basis was $5270 (Table 4).
Chronic  MS-related  costs.  Ongoing MS-related
health care costs were accounted for separately from
relapse-related costs. Separate monthly costs were
assigned to each disability level (Table 4). Although
data available on costs of MS in the US are limited
[2,34–37], we used two studies, Inman [36] (1987)
and Whetten-Goldstein et al. [2] (1998), to derive
cost estimates by EDSS level. These were cross-
sectional national surveys that reported data on
costs of multiple sclerosis including direct medical
costs, informal care, and lost earnings.
Cost-effectiveness analysis. Methods of incremen-
tal cost-effectiveness analysis were used [8]. The
incremental cost-effectiveness ratio is the difference
in time-discounted costs between the evaluated
strategy and the comparison strategy divided by the
difference in time-discounted QALYs between the
two strategies. Results are reported in dollars per
QALY.
Sensitivity Analysis
One-way sensitivity analyses were performed on all
variables listed in Tables 2 to 4 as well as on treat-
ment duration  (0–40 years),  duration  of  side
effects  (0–60 months), discontinuation time frame
(0–60 months), and rate of time preference (0–
10%). Ranges for the sensitivity analyses were
developed using 95% conﬁdence intervals when pri-
mary data were available or guided by ranges in the
literature if primary data were not available. Addi-
tional sensitivity analyses were performed to
explore the effects of delaying treatment until
higher levels of disability are reached, delaying
treatment until secondary progressive disease has
been diagnosed, including patient preferences
instead of community values for health states, and
the inclusion of lost wages as a cost of illness.
A key set of sensitivity analyses was performed to
evaluate the assumption regarding persistence of
treatment beneﬁts. In the base-case analysis, the
time horizon of the analysis is equal to the treat-
ment duration. In an alternate analysis, we evaluate
the cost-effectiveness of speciﬁc treatment durations
(5  and  10 years)  over  longer  time  horizons  of  up
to  30 years  beyond  the  end  of  treatment.  Once
patients have discontinued treatment, they are
expected to follow the natural history of the disease.
Beneﬁts due to delayed progression accrued during
treatment are retained, but probabilities of disease
progression following treatment are assumed to be
the same as those prior to treatment (i.e., simulated
patients will “return” to the natural history sub-
model at a less-disabled EDSS level than without
treatment). In this set of analyses we evaluate the
cost-effectiveness of 1) 5-year treatment duration;
2) 10-year treatment duration; and 3) discontinua-
tion of treatment after a patient has reached EDSS
level 6, when the beneﬁts persist up to 30 years
beyond treatment.
Two- and three-way sensitivity analyses were
performed on variables for which the results were
sensitive in the one-way sensitivity analysis. A prob-
abilistic sensitivity analysis was performed using
Monte Carlo simulation in which variables were
simultaneously varied. Probability distributions for
the parameters in the Monte Carlo sensitivity anal-
ysis were assumed to be lognormal for costs and to
follow a beta distribution for effects and quality
adjustments. Ranges in Tables 2 to 4 were used to
derive 95% conﬁdence intervals.
Results
Base Case Analysis
Under base-case assumptions, interferon beta-1a
(IFNB-1a) provided more health beneﬁts and was
more costly than no treatment for both men and
women, with resulting cost-effectiveness ratios of
$1,838,000/QALY for men and $2,218,000/QALY
for women (Table 5). Ten-year treatment with
IFNB-1a provided an additional 0.030 QALYs, or
11 additional quality-adjusted life days, for women
and 0.036 QALYs, or 13 additional quality-
adjusted life days, for men. IFNB-1b was less effec-
tive and more costly than no treatment (i.e.,
strongly dominated), and glatiramer had a higher
incremental cost-effectiveness ratio but lower cost
compared with IFNB-1b (i.e., glatiramer acetate
was ruled out through extended dominance).
Sensitivity Analysis
In one-way sensitivity analyses, the results were
most sensitive to changes in treatment duration, dis-
ability level at initiation of treatment, drug costs,
rate of disease progression, disutility and duration
of treatment side effects, and treatment effects on
disease progression (Table 6).
Treatment  duration.  The cost-effectiveness ratio
varied substantially with the duration of treatment
(Fig. 2); however, the cost-effectiveness exceeded
$200,000/QALY under the most favorable scenario.
If treatment duration was extended to 40 years, the
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cost-effectiveness ratios for IFNB-1a decreased to
$250,000/QALY for women and $235,000/QALY
for men. For treatment duration of less than or
equal to 6 years, not treating was the least costly
and most effective option because the disutility
associated with treatment side effects outweighed
the beneﬁts of treatment. For treatment duration
between 6 and 9 years, treatment with glatiramer
acetate was the most effective strategy. For treat-
ment duration of 10 years or more, treatment with
IFNB-1a was the most effective strategy.
Disability level at initiation of treatment. The base-
case analysis assumed that treatment was initiated
Table 5 Results of  base case analysis, 10-year treatment duration
Strategy
Total 
cost
Incremental
cost
QALY 
increase
due to 
treatment
beneﬁts
QALYs lost
due to  
treatment  
side
effects
Total 
QALYs
Incremental 
QALYs $/QALY
All strategies
Women
No treatment $11,290 7.926
Glatiramer acetate $72,356 $61,066 0.053 0.029 7.950 0.024 Dominated
IFNB-1a $76,959 $4,603 0.080 0.051 7.955 0.005
IFNB-1b $78,134 $1,175 0.073 0.088 7.911 (0.045) Dominated
Men
No treatment $11,169 7.855
Glatiramer acetate $74,023 $62,854 0.056 0.029 7.882 0.027 Dominated
IFNB-1a $76,645 $2,622 0.086 0.051 7.891 0.009
IFNB-1b $78,611 $1,966 0.078 0.088 7.845 (0.046) Dominated
Undominated strategies
Women
No treatment $11,290 7.926
IFNB-1a $76,959 $65,669 7.955 0.030 $2,217,736
Men
No treatment $11,432 7.855
IFNB-1a $76,879 $65,447 7.891 0.036 $1,838,227
Table 6 Sensitivity analyses for interferon beta-1a
Parameter
Range of  cost-effectiveness ratios ($/QALY)
Women Men
Base case 2,218,000 1,838,000
One-way sensitivity analyses:
Cost of  treatment 50% of  base case 1,112,000 924,000
Cost of  treating a severe relapse 50% of  base case 2,236,000 1,852,000
Monthly costs for each disability level Low 2,226,000 1,845,000
High 2,043,000 1,670,000
30 ¥ base case 1,178,000 870,000
Lost earnings included* 2,185,000 1,808,000
Disease progression 50% higher 888,000 776,000
50% lower 10,132,000 8,798,000
Side effect duration (months) 0 (No treatment disutility) 819,000 759,000
60 No treatment preferred No treatment preferred
Probability of  treatment discontinuation
(monthly probability)
0.87% 2,148,000 1,806,000
1.62% 2,311,000 1,884,000
Treatment effects on
Percent reduction in disease progression 27.11% 2,526,000 2,337,000
50.34% 1,480,000 1,267,000
Percent reduction in relapse rate 13.40% 2,494,000 2,023,000
24.89% 1,994,000 1,683,000
Quality adjustments
Disability levels Lower bound 4,516,000 4,070,000
Upper bound 1,245,000 1,080,000
Medians 4,832,000 4,286,000
Relapse severity Lower bound 2,241,000 1,970,000
Upper bound 2,046,000 1,722,000
Patient-based preference weights 4,020,000 3,273,000
Discount rate 0% 1,632,000 1,403,000
10% 6,442,000 5,359,000
*Based on estimates from Sweden by Kobelt et al. (2003). This sensitivity analysis assumes that lost earnings are not captured in the utility weights and that some pro-
portion of  patients at each EDSS level can not work.
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during early stages of the disease, corresponding to
an EDSS level of 0, 1, or 2. An analysis assuming
that treatment does not begin until patients have
reached EDSS 3 to 5.5 resulted in cost-effectiveness
ratios  for  IFNB-1a  that  were  90%  lower  than
those in the base-case analysis, or approximately
$180,000/QALY for both women and men (Fig. 3
shows results for women). Extending treatment
duration to 30 or 40 years, in addition to deferring
treatment until EDSS 3 to 5.5, resulted in even
lower cost-effectiveness ratios between $80,000/
QALY and 90,000/QALY.
Treatment beneﬁts persist beyond treatment
period. Assumptions regarding the effect of treat-
ments on future disease progression have a dra-
matic impact on cost-effectiveness results (Fig. 3).
For both 5 and 10 years of treatment, cost-
effectiveness ratios drop to less than $350,000/
QALY if beneﬁts accrued during the treatment
period persist for 20 years or more following the
discontinuation of treatment. For 5 years of treat-
ment, cost-effectiveness ratios drop to less than
$100,000/QALY if beneﬁts accrue for 25 or more
years following treatment. A “best-case” analysis
in which treatment initiation is delayed until
EDSS levels 3 to 5.5 and beneﬁts persist for many
years beyond treatment duration is shown for
both 5- and 10-year treatment durations in
Figure 3. The cost-effectiveness ratios for this sce-
nario dropped to less than $100,000 per QALY
for both 5 and 10 years of treatment for both
men and women if beneﬁts persist for 5 or more
years beyond treatment duration. Similarly, cost-
effectiveness ratios for treatment in secondary
progressive patients fall below $100,000/QALY if
beneﬁts persist for 5 or more years beyond treat-
ment duration (Fig. 4).
For an alternative treatment strategy in which
patients initiate treatment at EDSS levels of 0
through  2.5  and  treatment  is  discontinued  once
a patient reaches EDSS level 6, cost-effectiveness
ratios also drop but remain above $200,000/QALY
Figure 2 Cost-effectiveness of  undominated strategies (IFNB-la)
with and without treatment disutility by treatment duration.
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Figure 3 Cost-effectiveness of  IFNB-1a
assuming treatment beneﬁts extend beyond
treatment duration for 5 and 10 years of
treatment for different disability levels at ini-
tiation of  treatment, women only.
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even when treatment beneﬁts accrued during treat-
ment persist for up to 30 years (Fig. 5).
Side effects. If we allowed side effects to persist
beyond 10 to 12 months, then no treatment became
the optimal strategy. Results were also sensitive to
the amount of disutility assumed for each treat-
ment. Since treatment effects were similar, as treat-
ment disutilities were varied the treatment with the
lowest disutility became the dominant strategy. If
treatments had no disutility associated with them
(i.e., there are no side effects from any of the treat-
ments), cost-effectiveness ratios decreased by about
60% to $820,000/QALY for women and $760,000
for men, assuming 10 years of treatment. When
treatment disutility was included in the analysis,
even treatments that completely halt disease pro-
gression and eliminate relapses have unfavorable
cost-effectiveness ratios ($350,000/QALY).
Costs. Our results were quite sensitive to changes
in drug costs; therefore substantially reducing the
cost of the drug may bring the cost-effectiveness
ratios for treatment closer to a range considered
favorable.  Varying  the  medication  cost  results  in
an almost proportionate change in the cost-
effectiveness ratio for IFNB-1a. For example, reduc-
ing the cost of IFNB-1b from $1095 per month to
Figure 4 Cost-effectiveness of  IFNB-1a
assuming treatment beneﬁts extend beyond
treatment duration for 5 and 10 years of
treatment in patients with secondary pro-
gressive MS.
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approximately $100 per month results in a cost-
effectiveness ratio of $200,000/QALY for men and
$240,000/QALY for women.
Results were not sensitive to changes in the cost
of treating a relapse or probability of treating a
relapse. Alternative assumptions for MS health state
costs also did not signiﬁcantly affect results. Scenar-
ios assuming chronic MS-related costs of as much as
10 times those in the base case resulted in cost-
effectiveness ratios within 30% of the base case.
Results also varied little with the inclusion of lost
earnings; cost-effectiveness ratios were only slightly
lower at $2,185,000/QALY for women and
$1,808,000/QALY for men.
Disease progression. Increasing the base-case esti-
mates of disease progression by 50% resulted in
cost-effectiveness ratios that were approximately
60% lower than in the base case. Decreasing the
base case estimates of disease progression by 50%
increased the cost-effectiveness ratios by a factor of
4.
Treatment  effects. Changes in treatment effects
regarding disease progression affected the cost-
effectiveness ratios more than treatment effects on
relapse rates. A large increase or decrease of the
baseline treatment effect on disease progression
resulted in cost-effectiveness ratios 25% below to
50% above base case results. Similar changes for
the treatment effect on relapse rate resulted in cost-
effectiveness ratios within 10% of the base case
(Table 6).
Results were also not sensitive to the probability
of discontinuing treatment. Assuming no patients
discontinue treatment, resulting ratios were within
10% of the base case.
Quality  adjustment. Using the 95% conﬁdence
interval upper and lower bound estimates for health
state utilities caused ratios to increase by up to
100% or decline by 35%. Changing relapse-related
utility weights, however, did not affect results much.
Using median instead of mean utility weights caused
the cost-effectiveness ratios to double.
Rate of time preference. As the annual discount
rate was varied from 0% to 10%, cost-effectiveness
ratios changed from $1,600,000/QALY for women
and $1,400,000/QALY for men to $9,415,000/
QALY for women and $5,360,000/QALY for men.
Multi-way  sensitivity  analyses. Two-way sensitiv-
ity analyses resulted in cost-effectiveness ratios from
$400,000/QALY to $900,000/QALY for women
and men. Scenarios involving faster disease progres-
sion or no disutility of treatment resulted in the
lower end of the range.
Three-way sensitivity analyses produce results
with ratios from $240,000/QALY to 1,245,000/
QALY, or 10 to 30% of base case results. The most
favorable scenario assumed faster disease progres-
sion, a 50% reduction in drug costs, and no treat-
ment disutility and had cost-effectiveness ratios of
$260,000/QALY for women and $240,000/QALY
for men.
Using preferences for quality adjustments
assessed by MS patients [28] resulted in considera-
bly higher cost-effectiveness ratios of $4,020,000
for women and $3,273,000/QALY for men.
Probabilistic  sensitivity  analysis. Interferon beta-
1a was the optimal strategy in 56% of the trials.
Glatiramer acetate was optimal 33% of the time,
and IFNB-1b was optimal 7% of the time. In 5% of
the trials, no treatment was the best strategy.
Because the effects of the treatments are so similar,
each of the treatment strategies could be domi-
nated, extended dominated, or preferred in any
given trial.
Cost-effectiveness ratios remained unfavorable
for most scenarios generated in the probabilistic
sensitivity analysis. More than 70% of the scenarios
resulted either in dominance by no treatment or in
cost-effectiveness analyses greater than $1,000,000/
QALY.
Discussion
We used the currently recommended approach to
evaluate the cost-effectiveness of treatments for
patients with newly diagnosed non-primary-
progressive MS. Our results for the three treatment
strategies are unfavorable under a wide range of
assumptions. Costs, effects, and quality-of-life ben-
eﬁts are quite similar among the three immunomod-
ulatory treatments. Based on the published pivotal
clinical trial data, assumptions of slightly better
effects of IFNB-1a in slowing disease progression
and better effects on relapse reduction for glati-
ramer acetate and IFNB-1b drive which treatment
strategy dominates the others in our analysis. With
these assumptions, IFNB-1a was the best strategy in
terms of health outcome. IFNB-1b was disadvan-
taged relative to the other two because of the higher
disutility associated with treatment. Of note, the
quality of the efﬁcacy data differs between treat-
ments, since the pivotal clinical trials for these ther-
apies focused on different primary endpoints. Small
changes in reported treatment effects, as additional
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data become available, will likely affect which treat-
ment is most effective in a cost-effectiveness analy-
sis. The most effective treatment strategy may
change with new data, but the associated cost-
effectiveness ratios are likely to remain similar as
long as the updated costs, health beneﬁts, and side-
effects of the treatments remain similar.
Reports of the cost-effectiveness of IFNB-1b are
available from other countries [38–46]. Most eval-
uated cost-effectiveness for a more disabled popu-
lation, and all except one evaluated only IFNB-1b.
The  study  by  Parkin  and  others  (1998)  modeled
a more-disabled population (EDSS 3–7) and esti-
mated cost effectiveness at £328,000/QALY for 5-
year treatment duration. Their results are similar to
those reported in our sensitivity analysis for initiat-
ing treatment in patients at later stages of diseases.
Forbes et al. reported a cost-effectiveness ratio of
£1,024,667/QALY for IFNB-1b treatment in sec-
ondary progressive MS for patients in the UK,
which is similar to our results [41]. Brown and col-
leagues did not measure effectiveness in QALYs,
which makes a comparison with our results difﬁcult
[38,39]. Kendrick and Johnson (2000) reported
cost-effectiveness ratios as low as £27,000/QALY,
but this analysis evaluated a more disabled popula-
tion and included markedly different assumptions
regarding treatment effectiveness, disease progres-
sion, and quality adjustments.
The analyses by Kendrick and Johnson (2000)
and Chilcott and others (2003) are the only analyses
of the interferon betas to yield favorable cost-
effectiveness ratios. The Kendrick and Johnson
model included several assumptions which were
biased toward more favorable cost-effectiveness
ratios for treatment when compared with the
assumptions used in our model: larger differences in
utility between disability levels, a more favorable
interpretation of the clinical trial data on treatment
effects on delaying disease progression, a more dis-
abled population, and a sustained effect on disease
progression. In contrast, our analysis includes pro-
spectively collected utility inputs and mean treat-
ment effects from the pivotal Phase III clinical trials.
Sensitivity analyses evaluate the effect of varying the
last two assumptions: a more disabled population at
initiation of treatment and sustained effect of
treatment beneﬁts. Changing these last two assump-
tions does indeed result in more favorable cost-
effectiveness ratios of less than $100,000/QALY,
results similar to those reported by Kendrick and
Johnson (2000) (Fig. 4). Once treatment beneﬁts
continue to accrue beyond the duration of treat-
ment, cost-effectiveness improves because the
beneﬁts of delaying progression to very disabled
and more costly (both in terms of dollars and
quality-adjusted life years) health states are
included. An interesting result of this sensitivity
analysis is that cost-effectiveness improves as treat-
ment duration decreases. Kendrick and Johnson
model the long-term effects of only 2 years of treat-
ment followed by 18 years of beneﬁt accrual. We
have modeled 5 and 10 years of treatment followed
by up to 35 years of beneﬁt accrual and ﬁnd favo-
rable cost-effectiveness results for 5 years of treat-
ment. In our model, modeling the effect of 2 years
of treatment followed by 18 years of beneﬁt accrual
results in ratios of $110,000/QALY for men and
$120,000/QALY for women; however, a treatment
duration of only 2 years is unlikely unless the
patient does not tolerate treatment or develops neu-
tralizing antibodies to the beta interferons. In clin-
ical practice, patients who tolerate these therapies
will often remain on them for 5 or more years of
treatment but may discontinue once they start
exhibiting signs of progressive disease, for which
the effectiveness of these treatments has not been
established. Such a treatment strategy, treatment
discontinuation once signs of progressive disease
are apparent, is approximated in our model by hav-
ing patients discontinue treatment once they have
reached EDSS level 6. The cost-effectiveness of this
treatment strategy remains above $200,000/QALY
even if beneﬁts accrue for the remaining life expect-
ancy of the patient (Fig. 5). Results from the anal-
ysis performed by Chilcott and others on behalf of
the UK National Institute for Clinical Excellence
show cost-effectiveness ratios of under $100,000/
QALY for the beta interferons but are difﬁcult to
compare to our results since key modeling inputs
such  as  costs  and  quality  of  life  adjustments  for
the Chilcott model are not available (classiﬁed as
“commercial in-conﬁdence”). Using the qualitative
description of their quality adjustments provided in
their paper, we attempted to model a scenario in
which there was a larger difference in utility values
between EDSS health states. The clinical strategy in
their model is most similar to the scenario shown in
our Figure 5 for a 20-year time horizon. If we adjust
for larger differences in quality adjustments
between health states, the cost-effectiveness ratios
drop to about $200,000 per QALY for IFNB-1a.
Our results for patients with secondary progres-
sive MS are much more favorable than those for
patients with newly diagnosed MS (Fig. 5). They are
slightly higher than those presented by Kobelt and
colleagues which were $39,250/QALY using clinical
trial data and $25,700/QALY using natural history
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data [44,45]. Their analysis differs from ours in that
it assumes 33 months of interferon treatment dur-
ing a 10-year time frame, uses quality-of-life adjust-
ments based on the EQ-5D, and does not include
any adjustment for treatment side effects. All of
these assumptions would result in more favorable
cost-effectiveness results. If patients delay treatment
until the onset of secondary progressive MS, cost-
effectiveness ratios are much more favorable. The
most recent analysis by Kobelt and colleagues eval-
uates treatment for a mixed population of patients
with relapsing-remitting or secondary progressive
MS with cost-effectiveness ratios considerably
lower than our estimates for a newly diagnosed
cohort [46].
Time horizon for base case analyses ranges from
2.5 years to 40 years in other studies [38–46]. We
selected a base case time horizon of 10 years for our
analysis since at the start of our study it was antic-
ipated that new treatments for MS may become
available within that time frame. Because results
were sensitive to this assumption, we have included
sensitivity analyses for 5 to 40 years to allow com-
parison to other studies.
Explicitly incorporating the loss in quality of life
due to treatment side effects and administration
provides insight into the high discontinuation rates
associated with the immunomodulatory treatments.
For treatment duration less than or equal to 6 years,
we found that beneﬁts of treatment did not out-
weigh the disutility associated with the side effects
and treatment discomfort. If treatment effects
beyond 6 years are not considered, then our model
predicts that declining or discontinuing treatment
would be the patient’s preferred strategy. Although
results were quite sensitive to changes in drug costs,
substantially reducing the cost of the drug by a
factor of 10 would be needed to bring the cost-
effectiveness ratios for treatment closer to a range
considered favorable when treatment disutility is
included in the analysis.
There are some limitations regarding simplifying
assumptions made in this analysis. We do not
explicitly model the effects of age at onset, relapse
frequency, or type of symptoms at onset on disease
progression. Being able to stratify by these charac-
teristics could result in more favorable cost-
effectiveness ratios for treating subgroups with
faster expected disease progression. For example, if
a newly diagnosed patient is male, 40 years old, has
symptoms and signs of cerebellar dysfunction, and
has more frequent relapses that are likely to predict
a more progressive course of disease, treatment with
immunomodulatory treatments will have more
favorable cost-effectiveness ratios. Using data from
an analysis that estimates the effect of certain vari-
ables on median length of time to reach DSS6 [47],
we conducted a “what-if” analysis for this hypo-
thetical patient that resulted in cost-effectiveness
ratios approximately 50% lower than base case
results. On the other hand, patients presenting with
optic neuritis and purely sensory symptoms that are
associated with a more benign course of disease
would have less favorable cost-effectiveness ratios
as compared with our base case analyses.
The frequency of other illnesses that could affect
mortality does not appear to be increased in persons
with MS, with the exception of suicide [20,47]. The
elevated risk of suicide associated with MS was not
included in our analysis. While some studies [48,49]
have suggested a possible increase in suicide risk in
patients treated with interferon-beta therapies, the
signiﬁcance of this may have been overestimated.
We did not incorporate this into our assumptions.
We also assumed that once patients reach a signiﬁ-
cant level of disability, it is more difﬁcult to identify
individual relapses, and that the costs and quality-
of-life effects of a relapse are outweighed by those in
the chronic MS state. If this is not the case, the effec-
tiveness of treatments that reduce relapse rate may
be somewhat underestimated in this analysis for
later stages of disease.
Recent cost data by individual EDSS levels were
not available, and costs by EDSS level were approx-
imated by applying weights from 1976 data to 1994
data. Annual costs for the average patient with MS
were remarkably similar across three available stud-
ies on costs related to MS treatments [2,34–36].
There have been no major advances in MS treat-
ment until the introduction of the drugs evaluated
in this analysis, and sensitivity analyses around
these estimates resulted in little change in the result-
ing cost-effectiveness ratios.
Our analysis was based solely on data from the
pivotal clinical trials. Inclusion and exclusion crite-
ria differed among trials, potentially limiting the
ability to compare results. We chose to model a
hypothetical newly diagnosed cohort rather than
use data from placebo arms in the clinical trials
because of the differences across study populations
and concern that these might not reﬂect the disease
progression of a “typical” MS patient. The hypo-
thetical cohort modeled in this analysis (mean age at
onset of 30 years, initial EDSS level between 0 and
2.5) differed from the trial populations on several
characteristics. The IFNB-1b trial reported a higher
relapse rate in the placebo arm when compared
with our hypothetical cohort or the IFNB-1a or
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glatiramer acetate trials. The IFNB-1b and glati-
ramer acetate trials were restricted to relapsing-
remitting patients while the IFNB-1a trial included
both relapsing-remitting and relapsing-progressive
MS. The hypothetical cohort included all non-
primary progressive MS patients. The primary
endpoint for the IFNB-1a trial was disability
progression, whereas relapse rate was the primary
endpoint for the other two drugs. The study popu-
lations in the IFNB-1b and glatiramer acetate trials
also included more disabled patients up to and
including EDSS level 5.5 and 5, respectively. On this
measure, the population in the IFNB-1a trial, which
included patients with EDSS levels from 1 to 3.5,
matched most closely to our entering hypothetical
cohort with EDSS levels from 0 to 2.5. Mean ages
were similar across the trials (34–36 years) and
slightly higher than for our hypothetical cohort.
Given these differences in characteristics, an analy-
sis based on simply extending the trial data beyond
2 years could result in different cost-effectiveness
ratios. Our objective in using a hypothetical cohort
was to diminish the effect of differences in trial
design on cost-effectiveness results. A recent analy-
sis by Kobelt and colleagues clearly demonstrates
the differences between placebo arm and natural
history data for patients with secondary progressive
MS [46].
Our results suggest that strategies of waiting to
initiate treatment until a patient has progressed to a
more-disabled health state or of limiting the dura-
tion of treatment are more cost-effective options. At
the same time, recent studies suggest that immu-
nomodulators may have better efﬁcacy when initi-
ated early in the course of disease, providing
support for a policy advocating earlier initiation of
treatment [50–52]. Although we assumed a con-
stant effect of the treatments over time, early effects
would have to be substantial to have an appreciable
impact on the cost-effectiveness of treatment.
These results underscore the need for MS treat-
ments that are not just more cost-effective but that
are more clinically effective. Beneﬁts provided by
currently available immunomodulatory treatments
are modest, even if one excludes the disutility of
treatment. For all three immunomodulatory
treatments, the beneﬁts provided by 10 years of
treatment are approximately 30 additional quality-
adjusted life days (days in perfect health) or less.
Once the disutility of treatment is included, these
beneﬁts drop to about 11 to 13 additional days in
perfect health for IFNB-1b, and even fewer days for
the other treatments. Despite minor differences in
the efﬁcacy reported in clinical trial results, the
interferon betas and glatiramer acetate are quite
similar regarding the modest beneﬁts they provide
for patients with MS and their associated cost-
effectiveness. New MS drugs will need to be both
less costly and more effective than the current
options to result in more favorable cost-effective-
ness ratios. Oral therapies currently in development
are likely to be associated with less discomfort in
administration, which would favorably improve
their economic proﬁle, but will also need to be more
effective than currently available treatments.
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